Published in Proc Natl Acad Sci U S A on November 01, 1986
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci U S A (1987) 1.04
Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1987) 0.91
Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A (1991) 0.85
Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1990) 0.82
Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet (1985) 2.51
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) (1983) 1.93
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res (1975) 1.72
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet (1983) 1.69
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) (1983) 1.67
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A (1984) 1.35
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1981) 1.34
Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med (1984) 1.33
The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate (1984) 1.06
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer (1980) 1.03
Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Proc Natl Acad Sci U S A (1985) 0.94
Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev (1983) 0.94
Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate (1983) 0.93
Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev (1983) 0.91
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest (1983) 0.87
Prolonged suppression of plasma LH levels in male rats after a single injection of an LH-RH agonist in poly(DL-lactide-co-glycolide) microcapsules. J Androl (1985) 0.86
Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model. Proc Natl Acad Sci U S A (1985) 0.86
Clearance of lung metastases of prostate carcinoma after treatment with LH-RH agonist. Lancet (1984) 0.85
Biologic and biochemical effects of mitoxantrone. Semin Oncol (1984) 0.84
Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol (1983) 0.83
Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology (1980) 0.83
Early effects of pinealectomy on LH and testosterone secretion in white-tailed deer. J Endocrinol (1984) 0.82
Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH. Prostate (1985) 0.81
An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma. Med Oncol Tumor Pharmacother (1984) 0.79
A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. Semin Oncol (1984) 0.77
Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab (1986) 0.77
Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH. Prostate (1986) 0.77
Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis. Int J Fertil (1989) 0.77
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun (1971) 2.67
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet (1985) 2.51
Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science (1971) 2.43
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun (1971) 2.29
Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science (1975) 2.00
Isolation and properties of porcine thyrotropin-releasing hormone. J Biol Chem (1969) 1.97
Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin. Gastroenterology (1976) 1.74
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet (1973) 1.68
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer (1997) 1.64
The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun (1969) 1.62
Hypothalamic regulatory hormones. Annu Rev Biochem (1978) 1.60
Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes (2001) 1.59
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A (1986) 1.59
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A (2000) 1.57
Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. Proc Natl Acad Sci U S A (1980) 1.54
Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1989) 1.52
Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab (2000) 1.49
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A (1984) 1.49
The regional distribution of somatostatin in the rat brain. Endocrinology (1975) 1.48
Activity and specificity of synthetic thyrotropin-releasing hormone in man. Biochem Biophys Res Commun (1970) 1.47
Some notes on the background of the isolation, determination of structure, synthesis, and early clinical trials of the luteinizing hormone- and follicle-stimulating hormone-releasing hormone. Am J Obstet Gynecol (1976) 1.47
Isolation and structure of somatostatin from porcine hypothalami. Biochemistry (1976) 1.46
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A (1989) 1.45
Solid phase synthesis of growth hormone-release inhibiting factor. Biochem Biophys Res Commun (1973) 1.44
Isolation and structure of hypothalamic MSH release-inhibition hormone. Biochem Biophys Res Commun (1971) 1.43
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod (1994) 1.41
Hypothalamic regulatory hormones. Science (1973) 1.41
New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res (1988) 1.41
Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man. N Engl J Med (1971) 1.40
Hypothalamic neurohormones regulating anterior pituitary function. Recent Prog Horm Res (1968) 1.36
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A (1984) 1.35
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst (1995) 1.35
Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril (1971) 1.35
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A (1995) 1.35
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1981) 1.34
Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med (1984) 1.33
Enhancement of DNA synthesis and cAMP content of mouse thymocytes by mediator(s) derived from adherent cells. J Immunol (1976) 1.33
The hypothalamus and reproduction. Am J Obstet Gynecol (1972) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal (1989) 1.28
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1995) 1.27
Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides (1984) 1.27
Radioimmunoassay for GH-release inhibiting hormone. Proc Soc Exp Biol Med (1975) 1.27
Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett (1985) 1.26
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1999) 1.25
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A (1997) 1.25
LH-RH agonists and antagonists. Int J Gynaecol Obstet (1980) 1.24
Growth hormone release inhibiting hormone in acromegaly. Br Med J (1974) 1.24
Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A (1999) 1.23
DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci I (1971) 1.23
Radioimmunoassay of somatostatin. Metabolism (1978) 1.22
Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat (1982) 1.22
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab (1993) 1.22
Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J Clin Invest (1976) 1.22
Clinical experience with hypothalamic releasing hormones. 1. Thyrotropin-releasing hormone. Recent Prog Horm Res (1972) 1.21
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A (1999) 1.21
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci U S A (1998) 1.20
Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med (1998) 1.20
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1994) 1.19
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A (2000) 1.19
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci U S A (1996) 1.17
Stimulation of release and synthesis of luteinizing hormone(LH) and follicle stimulating hormone(FSH) in tissue culture of rat pituitaries in response to natural and synthetic LH and FSH releasing hormone. Endocrinology (1972) 1.17
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol (2000) 1.16
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A (1994) 1.16
Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A (1999) 1.16
Structure of porcine thyrotropin releasing hormone. Biochemistry (1970) 1.15
The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus. J Biol Chem (1971) 1.15
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. Receptor (1993) 1.15
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer (2000) 1.15
Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) (1984) 1.15
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab (1999) 1.14
Aspects of hypothalamic regulation of the pituitary gland. Science (1978) 1.14
Hormone-like activity of a thymus humoral factor on the induction of immune competence in lymphoid cells. J Exp Med (1974) 1.14
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat (2000) 1.13
Clinical experience with hypothalamic releasing hormones. 2. Luteinizing hormone-releasing hormone and other hypophysiotropic releasing hormones. Recent Prog Horm Res (1972) 1.13
Letter: Immunohistochemical localization of somatostatin in the rat pancreas. J Histochem Cytochem (1975) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci U S A (1988) 1.11
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer (1997) 1.11
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci U S A (1996) 1.11
Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep (1984) 1.10
Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer (1990) 1.10
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem (1976) 1.10
Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology (1974) 1.10